Últimas noticias sobre Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa

Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Y-mAbs Therapeutics Inc

Despite claiming over 100,000 lives annually, the U.S. overdose crisis received minimal attention during the recent presidential campaign, which concluded with Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/11/41776510/cannabis-industry-leaders-react-to-trump-victory-expect-changes">victory</a>. This oversight comes as overdose deaths continue to rise among Black and Indigenous Americans, revealing a growing racial disparity in the epidemic.
<h3 class="wp-block-heading">Rising Racial Disparities In Overdose Deaths</h3>
According to a Stateline analysis of federal data <a href="https://kentuckylantern.com/2024/11/04/overdose-deaths-are-rising-among-black-and-indigenous-americans/">covered</a> by Tim Henderson, overdose deaths among white Americans have declined, but deaths among people of color have increased. In 2023, Black and Native Americans experienced overdose death rates of 49.5 and 39.8 per 100,000 people, respectively, surpassing white rates. Health experts attribute this to a lack of targeted resources and funding in nonwhite communities.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;It is our contention that Black harm reduction isn't about drug use, it's about the harms of not being a white person in this country,&#8221; said Tracie Gardner, co-director of the National Black Harm Reduction Network. Communities of color often struggle to access harm reduction services, which are predominantly designed and led by white institutions.
<h3 class="wp-block-heading">Minimal Campaign Attention</h3>
Throughout the campaign, Trump and his opponent, Vice President Kamala Harris, <a href="https://www.benzinga.com/markets/cannabis/24/10/41299527/kamala-harris-defends-immigration-policy-at-latino-town-hall-criticizes-trumps-border-stance">focused largely on border security and drug enforcement</a> rather than harm reduction strategies.&nbsp;
As a recent Fitler Mag <a href="https://filtermag.org/overdose-presidential-election/">article</a> notes, Trump&#8217;s official platform emphasized escalating the drug war, proposing measures like deploying the U.S. Navy to impose a &#8220;full Fentanyl Blockade&#8221; and cracking down on cartels. Harris, while mentioning a commitment to ending the opioid epidemic, highlighted her background in prosecutions and supported increased border security measures.
Public health experts criticize this approach for failing to address the root causes of the crisis. Kassandra Frederique, executive director of the Drug Policy Alliance, noted that efforts have &#8220;ultimately fallen short of the scale and magnitude this crisis demands.&#8221;
<h3 class="wp-block-heading">Rising Demand For Narcan</h3>
Amid this policy void, demand for naloxone—commonly known by the brand name Narcan—is increasing sharply. Over 250 companies, universities and organizations have pledged to provide free doses of the overdose-reversing medication, <a href="https://www.npr.org/sections/shots-health-news/2024/10/08/nx-s1-5145832/250-companies-schools-and-organizations-pledge-to-provide-overdose-antidote-naloxone">according</a> to NPR. Major corporations like Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and the National Hockey League are participating in this national effort to curb fatalities.
White House officials noted that the wider availability of naloxone has contributed to a recent 10% decline in overall overdose deaths. &#8220;From airlines to classrooms, from offices to sports arenas, we are grateful to have hundreds of voluntary commitments from organizations and businesses across the country,&#8221; stated Dr. Rahul Gupta, the Biden administration&#8217;s drug czar, prior to the election.
However, experts caution that fatalities remain high, especially among marginalized communities.
<h3 class="wp-block-heading">Emergent BioSolutions Sees Stock Surge</h3>
Meanwhile, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), the manufacturer of Narcan, has seen its stock perform strongly in 2024. With a diverse portfolio addressing public health threats, the company&#8217;s financial recovery and strategic government contracts position it favorably in the market, <a href="https://www.insidermonkey.com/blog/emergent-biosolutions-inc-ebs-a-standout-among-best-performing-cheap-stocks-in-2024-1371074/">noted</a> Insider Monkey. EBS reported significant revenue growth and reduced debt, contributing to a year-to-date share price gain of over 280%.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31549189/fda-approves-over-the-counter-sale-of-opioid-reversal-drug-narcan">FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan</a>
Analysts attribute part of Emergent&#8217;s success to the increasing recognition of naloxone&#8217;s importance in combating the overdose crisis. As more organizations stock Narcan, the company&#8217;s role becomes ever more critical.
<h3 class="wp-block-heading">Barriers To Harm Reduction Access Persist</h3>
As the new administration takes office, the neglect of the overdose crisis in election debates raises questions about the future of <a href="http://benzinga.com/topic/harm-reduction">harm reduction</a> policies under the new administration. Advocates urge the government to prioritize effective strategies over punitive measures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41780260/canopy-growth-and-other-top-cannabis-companies-to-report-earnings-will-results-get-pot-stocks-on">Canopy Growth And Other Top Cannabis Companies To Report Earnings: Will Results Get Pot Stocks On Track Following Post-Election Dip?</a></li>
</ul>

Cannabis

Government

News

Health Care

Politics

AMZN

Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise

WIIM

ADMA

ADMA Biologics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and FY25 revenue guidance.

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) lowers FY2024 sales outlook from $45.00 million-50.00 million to $43.00 million-45.00 million.

Guidance

TACT

Transact Technologies Lowers FY2024 Sales Guidance from $45.00M-50.00M to $43.00M-$45.00M  VS Est. $47.16M

Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.04 by 250 percent. This is a 366.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $292.765 million which beat the analyst consensus estimate of $289.601 million by 1.09 percent. This is a 6.45 percent decrease over sales of $312.944 million the same period last year.

Earnings

Earnings Beats

FNKO

Funko Q3 2024 Adj. EPS $0.14 Beats $0.04 Estimate, Sales $292.765M Beat $289.601M Estimate

System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. The company reported quarterly sales of $88.832 million which beat the analyst consensus estimate of $86.629 million by 2.54 percent. This is a 1.15 percent increase over sales of $87.818 million the same period last year.

Earnings Misses

System1 Q3 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $88.832M Beat $86.629M Estimate

Mexco Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) reported quarterly earnings of $0.15 per share. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported $1.75 million in sales this quarter. This is a 24.32 percent increase over sales of $1.41 million the same period last year.

Mexco Energy Q2 EPS $0.15 Up From $0.12 YoY, Sales $1.75M Up From $1.41M YoY

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

RXST

RxSight shares are trading lower. The company reported Q3 financial results.

EPRX

Eupraxia Pharmaceuticals Reports Q3 Net Income Of $(6.0)M, Down From $(4.9)M Loss Last Year

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 6.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $18.957 million which beat the analyst consensus estimate of $18.852 million by 0.56 percent. This is a 25.94 percent increase over sales of $15.052 million the same period last year.

TELA

TELA Bio Q3 2024 GAAP EPS $(0.42) Misses $(0.41) Estimate, Sales $18.957M Beat $18.852M Estimate

Tuscows Q3 Revenue $92.297M Up From 86.971M YoY

LCID

Lucid Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) .

PBYI

Puma Biotechnology expects Q424 Net Product Revenue: $46M-$48M; FY2024: $187M-$190M (Prev. $183M-$190M).

KTOS

Kratos Defense & Security shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Offerings

Valley National Bancorp Announces Proposed Common Stock Offering

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.08 by 112.5 percent. The company reported quarterly sales of $330.399 million which missed the analyst consensus estimate of $382.239 million by 13.56 percent. This is a 17.46 percent decrease over sales of $400.268 million the same period last year.

Bloom Energy Q3 2024 Adj. EPS $(0.01) Misses $0.08 Estimate, Sales $330.399M Miss $382.239M Estimate

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2025 GAAP EPS guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 analyst estimate..

Chesapeake Utilities Affirms FY2025 GAAP EPS Guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 Est

CPRI

Capri Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2024 GAAP EPS guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 analyst estimate..

Chesapeake Utilities Affirms FY2024 GAAP EPS Guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 Est

Buybacks

TRIN

Trinity Capital Inc. Announces Stock Repurchase Program Of Up To $30M

In a report released today, Nicole Germino from Truist Financial reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report), with a pr...

Truist Financial Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)

Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout...

Buy Rating Affirmed for Y-Mabs Therapeutics Amid Solid R&D Prospects and Resilient Financial Performance

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Y-Mabs Therapeutics (YMAB – R...

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Y-Mabs Therapeutics (YMAB – Research Report), Resm...

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) and Bayer (GB:0P6S)

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (YMAB – Research Report), with a price ...

Morgan Stanley Remains a Sell on Y-Mabs Therapeutics (YMAB)

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

JonesTrading analyst Justin Walsh has reiterated their bullish stance on YMAB stock, giving a Buy rating today. Justin Walsh's rating is based on s...

Optimistic Buy Rating for Y-Mabs Therapeutics Driven by Innovative SADA PRIT Technology and Strategic Advancements

Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan

The latest update is out from Y-Mabs Therapeutics ( ($YMAB) ). Y-mAbs Therapeutics has signed an exclusive agreement with Nobelpharma to develop an...

Y-mAbs Partners with Nobelpharma for Japan Expansion

TLRY

YMAB

Management

Press Releases

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Participate in Upcoming Investor Conferences in September

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in October

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Comments

Y-mAbs Therapeutics

Noticias

Últimas noticias sobre Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL